BNP Paribas Financial Markets Has $173,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

BNP Paribas Financial Markets decreased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 46.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,325 shares of the company’s stock after selling 9,827 shares during the period. BNP Paribas Financial Markets’ holdings in Arcus Biosciences were worth $173,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Arcus Biosciences by 8.7% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock valued at $11,336,000 after acquiring an additional 59,273 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Arcus Biosciences by 11.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock valued at $8,669,000 after purchasing an additional 59,536 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Arcus Biosciences by 17.8% during the 3rd quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after buying an additional 28,307 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Arcus Biosciences during the 2nd quarter worth approximately $1,286,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Arcus Biosciences by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company’s stock valued at $455,000 after buying an additional 2,123 shares during the period. Institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on RCUS. Wells Fargo & Company began coverage on Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright reissued a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Finally, Barclays boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $34.00.

Arcus Biosciences Stock Down 2.6 %

Arcus Biosciences stock opened at $16.08 on Wednesday. Arcus Biosciences, Inc. has a fifty-two week low of $13.52 and a fifty-two week high of $20.31. The firm has a market capitalization of $1.47 billion, a PE ratio of -5.10 and a beta of 0.88. The company’s 50-day moving average is $16.49 and its 200-day moving average is $16.07. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $48.00 million for the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter in the prior year, the business earned ($0.94) EPS. The firm’s revenue for the quarter was up 50.0% on a year-over-year basis. Sell-side analysts anticipate that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.